Recursion Pharmaceuticals is a next-generation biopharmaceutical company that leverages advanced technology to decode biology and radically improve lives. The company operates in the TechBio sector, utilizing a combination of hardware, software, and data to industrialize drug discovery. Recursion's core service involves creating virtuous cycles of learning around vast datasets, which include 50 petabytes of proprietary biological, chemical, and patient-centric data. This data is used to profile genes and compounds through up to 2.2 million weekly wet lab experiments, producing 50 cell types at scale, including 1 trillion hiPSC-derived neuronal cells. The company also boasts a top 500 supercomputer, BioHive 1, to process these datasets and generate 6 trillion gene and compound relationships in their Maps.

Recursion serves a diverse range of clients, including pharmaceutical companies, research institutions, and healthcare providers. The company operates on a business model that focuses on strategic partnerships and collaborations, which are some of the most significant in the TechBio industry. Recursion makes money through these partnerships, as well as through the development and commercialization of new drugs discovered using their proprietary technology.

Keywords: biopharmaceutical, TechBio, drug discovery, datasets, gene profiling, wet lab experiments, supercomputer, cell types, strategic partnerships, commercialization.